Walden Biosciences

Walden Biosciences is pleased to announce completion of initial dosing of all subjects in the first cohort of a Phase 2 basket study evaluating WAL0921 as a treatment for chronic kidney diseases. The study initially evaluates two ascending doses in subjects with diabetic nephropathy to establish safety and confirm the pharmacodynamic effect of lowering suPAR that was seen in healthy subjects during the company’s Phase 1+ clinical study. Topline data from cohort 1 is expected by year-end 2024, with planned advancement into rare kidney disease cohorts in early 2025. #ChronicKidneyDisease #RenalDisease #suPAR #DrugDevelopment

Thanks to Canaccord Genuity for giving Walden Biosciences the opportunity to participate in their 44th Annual Growth Conference in Boston. We enjoyed sharing Walden Biosciences’ exciting story of how we are working to revolutionize the treatment paradigm for chronic kidney diseases and to review our progress as we advance our clinical trials for disease modifying approaches to chronic kidney diseases. #ChronicKidneyDisease #RenalDisease #DrugDevelopment #suPAR #CGDriven #DrivenByYourSuccess

Thanks to Canaccord Genuity for giving Walden Biosciences the opportunity to participate in their 44th Annual Growth Conference in Boston. We enjoyed sharing Walden Biosciences’ exciting story of how we are working to revolutionize the treatment paradigm for chronic kidney diseases and to review our progress as we advance our clinical trials for disease modifying approaches to chronic kidney diseases. #ChronicKidneyDisease #RenalDisease #DrugDevelopment #suPAR #CGDriven #DrivenByYourSuccess

The Walden team is looking forward to collaborating with one of the world’s leading experts in Mendelian randomization to advance suPAR science and better understand the causative role of elevated suPAR levels in kidney diseases. Read the full release here: https://lnkd.in/ePRVaNDf #ChronicKidneyDisease #renaldisease #suPAR #MendelianRandomization #Walden #DrugDevelopment

Walden Biosciences is proud to announce positive topline data from our Phase 1+ clinical study of WAL0921 in development for the treatment of kidney diseases. The data demonstrate WAL0921’s ability to directly target and rapidly reduce free suPAR levels, and may provide a truly novel and disease-modifying approach for many kidney diseases.  Read the release here: https://lnkd.in/ewTkrr7x #ChronicKidneyDisease #suPAR #RenalDisease #DrugDevelopment #PositiveData

Walden’s Chief Medical Officer, Andrew Blair, M.D., is looking forward to participating in the 6th Annual CKD Drug Development Summit taking place in Boston this week. The CKD Summit focuses on important advances in the development of new therapies for rare and common kidney diseases and is a forum for KOLs, industry experts, and regulators to explore kidney innovation for the next generation of drug development. #ChronicKidneyDiseases #DrugDevelopment #CKDSummit #RenalDiseases

Walden Biosciences was honored to be selected to present at William Blair’s Innovator Series: Private Biotechnology Stars. This one-day virtual event featured some of the most promising private biotechnology companies in the industry, including a Fireside Chat with Walden Biosciences Chief Scientific Officer, Alexander Duncan, Ph.D., and Matthew Phipps from the William Blair Research team. To read the research note William Blair issued on Walden Biosciences' innovative approach to transforming the treatment landscape for chronic kidney disease click here: https://lnkd.in/ebJ2K65m #chronickidneydisease #renaldisease #suPAR #dynamin #WilliamBlair #drugdevelopment